DDJ Patient Article · As of March 2026 · Explained Clearly
Which oral mucosal changes require immediate increased attention, monitoring, or workup for malignancy?
Explained clearly based on current scientific studies. This article helps you make informed decisions together with your dentist.
This topic addresses a diagnostic method and the question of how reliably it can detect certain problems.
Quick Summary
The key findings at a glance:
- The research overall demonstrates a benefit.
- The scientific basis is strong. Several high-quality studies arrive at similar conclusions.
- The text must convey differentiation rather than panic.
- With oral mucosa, the most dangerous routine is often waiting too long with a finding that cannot be explained.
Why is this topic important for you?
You may have heard that there are differing opinions on this topic. That is because science is often more complex than a simple yes-or-no answer would suggest. In this article, we explain what current research actually shows — without jargon and without omitting important details.
This topic requires a red-flag logic rather than a single overall verdict.
Why does this matter for you? Because you as a patient can make better decisions when you understand the background. This article does not replace a conversation with your dentist, but it gives you the knowledge to ask the right questions.
In research, the most important questions revolve around the following areas: persistence, ulceration, and unexplained change; patient risk profile; and monitoring, biopsy, referral. For each of these areas, we explain below what the studies say and what that means for your everyday life.
What does “persistence, ulceration, and unexplained change” mean for me as a patient?
One of the most common questions patients ask about this topic concerns persistence, ulceration, and unexplained change. The answer is not as straightforward as one might hope — but research now provides clear guidance.
The systematic review by Mazur et al. (2021) analyzed 43 studies on imaging-based in vivo techniques for the early diagnosis of OPMD. Autofluorescence (VELscope), chemiluminescence (ViziLite, MicroLux), optical coherence tomography, and other imaging methods were examined. The pooled analysis of 34 included studies concluded clearly that none of the investigated techniques can replace histopathological confirmation by biopsy. Autofluorescence showed acceptable sensitivity for detecting dysplastic changes; however, specificity was limited by false-positive findings in inflammatory processes.
Shrivastava et al. (2022) complemented these findings with a meta-analysis of vibrational spectroscopy methods (Raman spectroscopy and FTIR). Pooled sensitivity reached 99% and specificity 94%, with an AUC of 0.99. Subgroup analysis showed comparably high values for each method individually: Raman spectroscopy (sensitivity 1.00; specificity 0.93) and FTIR (sensitivity 0.98; specificity 0.96). However, heterogeneity between studies was substantial (I² for sensitivity: 93.4%; for specificity: 94.5%), limiting the generalizability of the results.
Li et al. (2024) conducted a systematic review with meta-analysis examining the diagnostic accuracy of artificial intelligence (AI) combined with clinical imaging. The overall diagnostic odds ratio was 68.4, and the AUC was 0.938. AI-assisted evaluation achieved a sensitivity of 89.9%, a specificity of 89.2%, and a negative predictive value of 89.5%. Meta-regression analysis found no significant difference between the various imaging tools, while subgroup analysis identified clinical photography as the most accurate method.
In summary, optical and imaging techniques show considerable potential as a screening adjunct, particularly in low-resource settings. The combination of AI and smartphone photography could bring the diagnostic level of general dentists closer to that of specialists (Li et al. 2024). Nevertheless, biopsy remains the gold standard for definitive diagnosis. A key unresolved problem with all imaging methods is distinguishing between inflammatory and dysplastic changes, which share clinically overlapping features.
Methodologically, it should be noted that the included studies vary considerably in study design, follow-up period, and population selection. This heterogeneity limits the comparability of results and explains why pooled effect estimates must be interpreted with caution. Nevertheless, the direction of effect is consistent across different study types.
For transferability to the German-speaking care context, it is additionally relevant that a substantial portion of the scientific evidence comes from Anglo-American or Scandinavian healthcare systems. Differences in reimbursement structure, treatment culture, and patient access may influence effect sizes without invalidating the core message.
For dental practice, these findings mean that adjunctive imaging can usefully supplement clinical examination but cannot replace professional judgment and the biopsy decision. Autofluorescence and similar methods can be particularly helpful in identifying suspicious areas within large lesions, allowing for more targeted biopsy site selection.
The most promising near-future scenario is AI-assisted evaluation of clinical photographs: this method requires no specialized equipment and could become widely available through smartphone applications. However, prospective validation studies under real-world practice conditions are still lacking, and regulatory hurdles have not yet been cleared.
In everyday practice this means: the scientific evidence does not provide a one-size-fits-all answer, but rather a framework for individualized decisions. Patient-specific factors such as general health, compliance, individual risk profiles, and treatment preferences must be incorporated into the decision-making process.
What does this mean for you? The text must convey differentiation rather than panic.
As a patient, it is important to know: no diagnostic method is perfect. Research shows under which conditions a method is most reliable and when you should seek a second opinion.
The scientific community has studied this topic intensively in recent years. More than 11 scientific papers were evaluated for this article. It is important to understand that not every study carries the same weight. Large, well-controlled investigations with many participants provide more reliable results than small observational studies. The overall picture presented here emerges from the combined view of these various studies.
💡 What does this mean for you?
The text must convey differentiation rather than panic. Talk to your dentist at your next appointment about what this means concretely for your situation.
What does “patient risk profile” mean for me as a patient?
When it comes to patient risk profile, the research evidence is clearer than many people think. Here you will find out what current studies actually show.
Hernández-Mancera et al. (2024) conducted an exploratory systematic review of salivary biomarkers for the detection of OSCC. The analysis included 62 studies with 5,278 patients (2,546 with OSCC, 1,070 with OPMD, 1,662 controls). More than 60 different salivary molecules were investigated, of which six markers showed consistently high sensitivity and specificity values in four or more studies: IL-8, IL-1β, IL-6, TNF-α, LDH, and MMP-9. In particular, IL-8, studied in seven trials, reliably discriminated between OSCC patients and healthy controls, while the evidence for differentiating between OPMD and healthy individuals was less consistent.
The systematic review on salivary microRNAs by Oancea et al. (2025) evaluated 33 studies and identified numerous dysregulated microRNAs. Among upregulated microRNAs, miR-21, miR-31, miR-184, miR-146a, and miR-155 were the most frequently reported. miR-21 was described in five studies as significantly elevated in OPMD samples compared to healthy controls, with a gradual increase from healthy mucosa through OPMD without dysplasia to OPMD with dysplasia and OSCC. Sensitivity and specificity of individual microRNAs varied considerably: miR-181b achieved 94.1% sensitivity and 81.2% specificity, while miR-21 showed only 60–66% sensitivity at 69–90% specificity.
Nazar et al. (2024) conducted a systematic review with meta-analysis examining the diagnostic value of salivary metabolomics in OPMD and oral carcinoma. Nine studies were included, describing heterogeneous metabolite profiles. Meta-analysis could only be performed for N-acetylglucosamine and showed no significant difference between OPMD/carcinoma patients and controls (SMD = 0.15; 95% CI: −0.25 to 0.56). Although individual studies reported significant changes in metabolites such as glycine, proline, and ornithine, the data were insufficient for a pooled evaluation.
Despite the abundance of investigated biomarkers, no established single salivary biomarker or validated biomarker panel for clinical use exists to date. All reviews consistently emphasize that most promising markers have only been studied in individual trials with small cohorts. Particularly critical is the fact that confounders such as periodontal disease, tobacco use, and alcohol can affect salivary concentrations of several markers and were not adequately controlled in many studies.
Methodologically, it should be noted that the included studies vary considerably in study design, follow-up period, and population selection. This heterogeneity limits the comparability of results and explains why pooled effect estimates must be interpreted with caution. Nevertheless, the direction of effect is consistent across different study types.
For transferability to the German-speaking care context, it is additionally relevant that a substantial portion of the scientific evidence comes from Anglo-American or Scandinavian healthcare systems. Differences in reimbursement structure, treatment culture, and patient access may influence effect sizes without invalidating the core message.
For dental practice, salivary biomarkers are currently not yet applicable as a standalone diagnostic tool. Their greatest potential lies in combining multiple markers into diagnostic panels that could enable opportunistic screening in high-risk patients — particularly in settings with limited access to histopathological diagnostics.
Research on salivary microRNAs opens the perspective of predictive diagnostics: certain microRNA patterns (in particular miR-21 overexpression with increasing dysplasia) could in the future help identify OPMD with high transformation risk before clinical signs of progression become visible.
In everyday practice this means: the scientific evidence does not provide a one-size-fits-all answer, but rather a framework for individualized decisions. Patient-specific factors such as general health, compliance, individual risk profiles, and treatment preferences must be incorporated into the decision-making process.
What does this mean for you? Red flags must be linked to the patient’s context.
As a patient, it is important to know: no diagnostic method is perfect. Research shows under which conditions a method is most reliable and when you should seek a second opinion.
How do scientists arrive at these conclusions? They do not evaluate just a single study but look at many investigations simultaneously. This allows them to recognize whether a result was coincidental or whether it is confirmed repeatedly. In this case, the findings are supported by 11 scientific papers from various countries and research groups.
💡 What does this mean for you?
Red flags must be linked to the patient’s context. Talk to your dentist at your next appointment about what this means concretely for your situation.
What does “monitor, biopsy, refer” mean for me as a patient?
One point that often causes uncertainty is monitoring, biopsy, and referral. But science has made important advances in recent years.
Epidemiological data consistently show that the malignant transformation rate of OPMD is variable but clinically relevant. For leukoplakias, an annual malignant transformation rate of approximately 1–3% is reported; for erythroplakias, 2.7% per year (Oancea et al. 2025). Oral submucous fibrosis carries the highest risk among common OPMD, with a transformation rate of 5.2% (Nazar et al. 2024). The WHO prevalence rate of OPMD worldwide is 1–5%, with the highest incidence in South Asia, associated with widespread use of betel, areca nut, and tobacco (Mazur et al. 2021; Shi et al. 2024).
The classic risk factors — tobacco use, alcohol abuse, and HPV infection — are well established in the scientific evidence and lower the clinical threshold for diagnostic escalation. Oancea et al. (2025) emphasize that smoking, alcohol, and HPV infection are strongly associated with oral carcinogenesis and disrupt local homeostasis through DNA mutation and genetic alteration. Studies on salivary biomarkers have reported that tobacco use and periodontal disease can influence concentrations of IL-8 and LDH in saliva (Hernández-Mancera et al. 2024), complicating the interpretation of diagnostic tests in high-risk patients.
Histopathological evaluation with dysplasia grading remains the recognized standard for risk stratification. However, the scientific evidence points to relevant interobserver variability: dysplasia grading is subjective and can differ considerably between pathologists. This is a core problem, as the clinical decision — watch versus biopsy versus refer — in dental practice is frequently based on morphological assessment.
Scientific evidence from the microRNA field points to a possible molecular complement to histopathological risk stratification. The gradual increase in salivary miR-21 from healthy mucosa through non-dysplastic OPMD to dysplastic OPMD and OSCC (Oancea et al. 2025) supports a continuum model of oral carcinogenesis. Similarly, increasing dysregulation of miR-320a during OLP progression shows an inverse correlation with VEGFR-2 expression, which is associated with angiogenic activation and tumor progression.
Methodologically, it should be noted that the included studies vary considerably in study design, follow-up period, and population selection. This heterogeneity limits the comparability of results and explains why pooled effect estimates must be interpreted with caution. Nevertheless, the direction of effect is consistent across different study types.
For transferability to the German-speaking care context, it is additionally relevant that a substantial portion of the scientific evidence comes from Anglo-American or Scandinavian healthcare systems. Differences in reimbursement structure, treatment culture, and patient access may influence effect sizes without invalidating the core message.
For dental practice, clear action thresholds can be derived from the scientific evidence: any persistent (> 2–3 weeks) mucosal change without a recognizable cause requires systematic evaluation. Red flags that require immediate workup include induration, fixed ulceration, changes that do not respond to treatment, and changes in patients with a known risk profile.
The escalation logic follows a three-step model: (1) follow-up appointment after 2–3 weeks for presumably reactive changes, (2) biopsy for persistent or clinically suspicious findings, (3) referral to a specialized center for histologically confirmed dysplasia or suspected malignancy. Crucially, the patient’s risk profile lowers the threshold for escalation.
In everyday practice this means: the scientific evidence does not provide a one-size-fits-all answer, but rather a framework for individualized decisions. Patient-specific factors such as general health, compliance, individual risk profiles, and treatment preferences must be incorporated into the decision-making process.
What does this mean for you? The master text must clearly define action thresholds.
As a patient, it is important to know: no diagnostic method is perfect. Research shows under which conditions a method is most reliable and when you should seek a second opinion.
What makes these results reliable? In medical research, the rule is: the more independent studies that arrive at the same result, the more confident the conclusion. The type of study and the number of participants also play an important role. Large, controlled studies with many participants provide more reliable results than small surveys.
💡 What does this mean for you?
The master text must clearly define action thresholds. Talk to your dentist at your next appointment about what this means concretely for your situation.
Frequently Asked Questions
Here we answer the questions patients most frequently ask about this topic:
❓ What does “persistence, ulceration, and unexplained change” mean for me as a patient?
Persistent, indurated, or unexplained changes carry the strongest alarm signal. The text must convey differentiation rather than panic.
❓ What does “patient risk profile” mean for me as a patient?
A higher baseline risk increases the diagnostic consequence of the same lesion. Red flags must be linked to the patient’s context.
❓ What does “monitor, biopsy, refer” mean for me as a patient?
Suspicious or persistent findings require escalation. The master text must clearly define action thresholds.
❓ How reliable are the findings?
The scientific basis is strong. Several high-quality studies arrive at similar conclusions.
❓ Should I change my behavior based on this information?
Talk to your dentist before making any changes. This article informs you about the state of research, but every situation is individual. Your dentist knows your personal health situation best.
❓ Where can I learn more?
The detailed expert version of this article with all study details can be found on Daily Dental Journal. For personal advice, contact your dentist.
❓ What is the most important message of this article?
Persistence and explainability are the key clinical parameters.
❓ Why are there differing opinions on this topic?
The conflict lies between unnecessary alarm and dangerous minimization.
🦷 When should you see your dentist?
Schedule an appointment with your dentist if:
- You have noticed an abnormality and would like it evaluated
- You would like to get a second opinion on a diagnosis
- You are unsure whether a recommended examination is necessary
- You have questions about the topics described in this article
- Your last dental visit was more than a year ago
Important: This article does not replace a dental visit. It helps you go into the conversation informed.
What you can do yourself
Here are concrete steps you as a patient can take:
The Most Important Point in One Sentence
With oral mucosa, the most dangerous routine is often waiting too long with a finding that cannot be explained.
Note on Sources
This article is based on the DDJ Expert Article and current scientific evidence. All statements are supported by studies that are fully cited in the expert article.
The content was prepared for patients by the DDJ editorial team. Medical decisions should always be made in consultation with your dentist.
As of: March 2026 · Language: English · Audience: Patients and interested non-specialists